维普期刊资源整合服务平台（V6.5）

189篇 您的检索式：作者名="Forst T"

选中清除导出查看参考文献查看引证文献引用追踪共10页首页上一页第1页下一页末页 /10 跳转

	题名	作者	年代	出处	被引量
1	Re- commendations for rma:agement of inWacra- nial haemorrhage:part I:spontaneous intracer- ebral haemorrhage :the European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Commit- tee显示文摘	Steiner T Kaste M Forsting M	2006	Cerebrovasc Dis2006，22，4：	1
2	Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients显示文摘	Forst T Hohberg C Pfutzner A	2009	Horm Metab Res2009，41，2：	1
3	Activation of endothelial nitric oxide synthase (eNOS) by C-peptide显示文摘	Kunt T Forst T Closs E	1998	Diabetologia1998，411，：	1
4	Effects of proinsulin C- peptide on nitric oxide,microvascular blood flow and erythrocyte Na+ ,K+-ATPase activity in diabetes mellitus type I显示文摘	Forst T De La Tour DD Kunt T	2000	Clin Sci (Lond)2000，98，3：	1
5	Microencapsulation ofprobiotic cells for food applications显示文摘	HEIDEBACH T FORST P KULOZIK U	2012	Critical Reviews m Food Sci- ence and Nutrition2012，52，4：	1
6	Efcacy and safety of canagliozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone显示文摘	Forst T Guthrie R Goldenberg R	2014	Diabetes Obes Metab2014，16，5：	1
7	Dapagliflozin,an SGLT2 inhibitor,for diabetes显示文摘	Hanefeld M Forst T	2010	Lancet2010，375，9733：	1
8	Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na^+ - K^+ - ATPase activity in diabetes mellitus type 显示文摘	Forst T Dufayet D Kunt T	2000	Clin Sci2000，98，3：	1
9	Exenatide once weekly versus lira- glutide once daily in patients with type 2 diabetes (DURATION-6) : a randomised, open-label study显示文摘	Buse J B Nauck M Forst T	2013	Lancet2013，381，9861：	1
10	Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects显示文摘	Pfutzner A Weber MM Forst T	2007	Expert Opin Pharmacother2007，8，12：	1
11	Interracial supramo显示文摘	McNa Forst er R J Keyes T E	2009	Phys ChemChemPhys2009，11，5：	1
12	Addition of liraglutide in patients with type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function显示文摘	Forst T Michelson G Ratter F	2012	Diabet Med2012，29，9：	1
13	High-sensitivity C-reactive protein as cardiovas- cular risk marker in patient with diabetes mellitus显示文摘	PfutznerA Forst T	2006	Diabetes Technol Ther2006，8，1：	1
14	Serum levels of substance P are decreased in patients with typeⅠ diabetes显示文摘	Forst T Schmidt S	2000	Exp Clin Endocrinol Diabetes2000，108，3：	1
15	Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients 显示文摘	Forst T Hohberg C Pftitzner A	2009	Horm Metab Res2009，41，2：	1
16	Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone显示文摘	Forst T Guthrie R Goldenberg R	2014	Diabetes Obes Metab2014，16，5：	1
17	Transglutaminase-in- duced caseinate gelation for the microencapsulation ofprobiotic cells 显示文摘	HEIDEBACH T FORST P KULOZIK U	2009	International Dairy Journal2009，19，2：	1
18	The oral DPP-4 inhibitor lina- gliptin significantly lowers HbAlc after 4 weeks of treatment in pa- tients with type 2 diabetes mellitus 显示文摘	Forst T Uhlig-Lasker B Ring A	2011	Diabetes Obes Metab2011，13，6：	1
19	Sorption of selected polycyclic aromatic hydrocarbons on soils in oil-contaminated systems显示文摘	Walter T Ederer H J Forst C	2000	Chemosphere2000，41，3：	1
20	Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study显示文摘	Langenfeld MR Forst T Hohberg C	2005	Circulation2005，111，19：	1

返回顶部每页显示：

共10页首页上一页第1页下一页末页 /10 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示